Davie, A., Traoré, S., Giovannitti, M., Pompilio, G., Lambton, M., Cakar, E. and Chatterjee, A. (2023) “Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy”, Global and Regional Health Technology Assessment, 10(1), pp. 62–69. doi: 10.33393/grhta.2023.2561.